Free Trial

Cardiol Therapeutics (TSE:CRDL) Stock Price Down 15.1% - What's Next?

Cardiol Therapeutics logo with Medical background

Key Points

  • Cardiol Therapeutics Inc. stock price fell by 15.1% to C$1.57, following a significant increase in trading volume of 264% on Wednesday.
  • The company has a current market capitalization of C$124.47 million and a P/E ratio of -2.95, indicating potential concerns over profitability.
  • Cardiol's lead drug candidate, CardiolRxTM, is an oral solution based on cannabidiol, aimed at treating heart disease through anti-inflammatory and anti-fibrotic therapies.
  • Looking to export and analyze Cardiol Therapeutics data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report) was down 15.1% during mid-day trading on Wednesday . The company traded as low as C$1.47 and last traded at C$1.57. Approximately 296,430 shares changed hands during mid-day trading, an increase of 264% from the average daily volume of 81,398 shares. The stock had previously closed at C$1.85.

Cardiol Therapeutics Price Performance

The company has a debt-to-equity ratio of 1.59, a current ratio of 2.49 and a quick ratio of 6.84. The stock has a market capitalization of C$116.17 million, a price-to-earnings ratio of -2.75 and a beta of 0.70. The stock's 50 day simple moving average is C$1.86 and its 200-day simple moving average is C$1.69.

About Cardiol Therapeutics

(Get Free Report)

Cardiol Therapeutics Inc NASDAQ: CRDL TSX: CRDL is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.

Featured Stories

Should You Invest $1,000 in Cardiol Therapeutics Right Now?

Before you consider Cardiol Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.

While Cardiol Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Tesla’s Future Unleashed: Elon’s Robotics Move Changes Everything
Top Trades: Massive Gains and Costly Mistakes to Avoid
NVIDIA Earnings: All Signs Point to More Growth Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines